Trial Profile

A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant two component COVID 19 vaccine Jiangsu Rec Biotechnology (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Rec-Biotechnology

28 Feb 2024 Status changed from active, no longer recruiting to completed.
07 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.
25 Apr 2023 Planned End Date changed from 1 Aug 2023 to 1 Nov 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com